Naber, Kurt G.
Tandogdu, Zafer
Köves, Bela
Bonkat, Gernot
Wagenlehner, Florian
Article History
Received: 7 June 2019
Accepted: 29 October 2019
First Online: 2 December 2019
Ethics approval and consent to participate
: Not applicable; this is a review article.
: Not applicable; this is a review article.
: KGN reports personal fees from Adamed, Apogepha, Aristo, Biomerieux, Bionorica SE, Daiichi Sankyo, Enteris Biopharma, Eumedica, GlaxoSmithKline, Gruenenthal Mexico, Helperby Therapeutics, Hermes, Medice, Meiji Seika Pharma, MerLion, MSD Sharp & Dohme, OM Pharma and Vifor, Paratek, Roche, Rosen Pharma, and Zambon.ZT reports personal fees from Bionorica SE.BK reports personal fees from Vifor Pharma, Bionorica, IBSA and Ferring.GB reports personal fees from Bionorica SE, Jansen, Lilly, GlaxoSmithKline, OM Pharma and Vifor.FW reports grants from Deutsche Forschungsgemeinsschaft and Deutsches Zentrum für Infektionsforschung, personal fees from Achaogen, Astellas, Bionorica, MSD, Leo-Pharma, Medpace, Merlion, Vifor, Paratek, Rempex, Rosen Pharma, VenatoRx, AstraZeneca, and Janssen, and other forms of financial support from Enteris BioPharm, Helperby, and Shionogi.